Lifeward获股东批准与Oramed达成战略合作——组建多元化生物医学公司

美股速递
Mar 13

Lifeward公司已获得股东批准,即将完成与Oramed Pharmaceuticals Inc(纳斯达克:ORMP)的战略合作。这一关键进展标志着两家公司正式整合资源,共同组建一家业务多元化的生物医学企业。此次合作将结合双方在医疗技术领域的专长,有望推动创新疗法的研发进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10